Comparison of Oral Apixaban and Heparin for Blood Clot Treatment in Cancer Patients

Introduction to the Study

Researchers at the Mayo Clinic have conducted a study evaluating the efficacy and safety of oral apixaban compared to heparin for treating blood clots in cancer patients. One in five cancer patients is at risk of developing venous clots, which pose significant health threats and rank as the second leading cause of death among this population.

Limitations of Conventional Treatments

The standard treatment for blood clots in cancer patients involves twice-daily injections of low-molecular-weight heparin. However, this method presents several drawbacks. The injections can lead to pain and bruising at the injection site and come at a high cost of nearly $100 per day. Additionally, many cancer patients experience low platelet counts and are vulnerable to heparin-induced thrombocytopenia, a clotting disorder. The risk of kidney injury from cancer and its treatments further complicates the use of heparin. Furthermore, the absence of a reliable antidote for heparin in cases of bleeding is a major concern.

Advantages of Oral Apixaban

Recently, direct oral anticoagulants, such as oral apixaban, have gained popularity for their numerous advantages over heparin. These medications can be taken orally, do not interact with food or other medications, and do not require regular monitoring of drug levels. However, until this study, there was uncertainty about their safe use in cancer patients for treating arterial clots and enhancing blood flow.

Study Findings and Presentation

The Mayo Clinic research team compared the efficacy and safety of oral apixaban with low-molecular-weight heparin in a clinical trial involving cancer patients. The results were presented at the annual meeting of the American Society of Hematology, held from December 1-4, 2018, in San Diego, California.

Research Methodology

The trial involved quality of life surveys conducted monthly over a six-month period to assess patient outcomes. The findings indicated that oral apixaban is both safe and effective for treating blood clots in patients undergoing cancer therapy. Notably, oral apixaban was linked to fewer major bleeding incidents and recurrent blood clots compared to low-molecular-weight heparin.

Patient Preferences and Future Implications

Patients in the study expressed a preference for oral apixaban over injectable dalteparin, suggesting that its use could enhance medication adherence among cancer patients requiring anticoagulation therapy.

Conclusion

The Mayo Clinic study supports the use of oral apixaban as a safe alternative for blood clot treatment in cancer patients, potentially improving their quality of life and treatment compliance.

Reference

Duggal, Pratibha. “Mayo Researchers Say Oral Apixaban Safe And Effective For Treating Blood Clots In Cancer Patients.” Mayo Clinic News Network, 2018. [Link](https://newsnetwork.mayoclinic.org/discussion/mayo-researchers-say-oral-apixaban-safe-and-effective-for-treating-blood-clots-in-cancer-patients/). Accessed 17 Dec 2018.